These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37625154)

  • 1. Medications for alcohol use disorder promote abstinence in alcohol-associated cirrhosis: Results from a systematic review and meta-analysis.
    Gratacós-Ginès J; Bruguera P; Pérez-Guasch M; López-Lazcano A; Borràs R; Hernández-Évole H; Pons-Cabrera MT; Lligoña A; Bataller R; Ginès P; López-Pelayo H; Pose E
    Hepatology; 2024 Feb; 79(2):368-379. PubMed ID: 37625154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medications for alcohol use disorder improve survival in patients with hazardous drinking and alcohol-associated cirrhosis.
    Rabiee A; Mahmud N; Falker C; Garcia-Tsao G; Taddei T; Kaplan DE
    Hepatol Commun; 2023 Apr; 7(4):. PubMed ID: 36972386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baclofen for alcohol use disorder.
    Agabio R; Saulle R; Rösner S; Minozzi S
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD012557. PubMed ID: 36637087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baclofen for alcohol use disorder.
    Minozzi S; Saulle R; Rösner S
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012557. PubMed ID: 30484285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systematic review and meta-analysis: Efficacy and safety of baclofen in patients with alcohol use disorder co-morbid liver diseases.
    Duan F; Zhai H; Liu C; Chang C; Song S; Li J; Cheng J; Yang S
    J Psychiatr Res; 2023 Aug; 164():477-484. PubMed ID: 37441998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acamprosate may be safer than baclofen for the treatment of alcohol use disorder in patients with cirrhosis: a first description of use in real-world clinical practice.
    Tyson LD; Cheng A; Kelleher C; Strathie K; Lovendoski J; Habtemariam Z; Lewis H
    Eur J Gastroenterol Hepatol; 2022 May; 34(5):567-575. PubMed ID: 35421022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate.
    Palpacuer C; Duprez R; Huneau A; Locher C; Boussageon R; Laviolle B; Naudet F
    Addiction; 2018 Feb; 113(2):220-237. PubMed ID: 28940866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controlled drinking-non-abstinent versus abstinent treatment goals in alcohol use disorder: a systematic review, meta-analysis and meta-regression.
    Henssler J; Müller M; Carreira H; Bschor T; Heinz A; Baethge C
    Addiction; 2021 Aug; 116(8):1973-1987. PubMed ID: 33188563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psychosocial and medication interventions to stop or reduce alcohol consumption during pregnancy.
    Minozzi S; Ambrosi L; Saulle R; Uhm SS; Terplan M; Sinclair JM; Agabio R
    Cochrane Database Syst Rev; 2024 Apr; 4(4):CD015042. PubMed ID: 38682758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
    Greene MC; Kane J; Alto M; Giusto A; Lovero K; Stockton M; McClendon J; Nicholson T; Wainberg ML; Johnson RM; Tol WA
    Cochrane Database Syst Rev; 2023 May; 5(5):CD013350. PubMed ID: 37158538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using a cascade of care framework to identify gaps in access to medications for alcohol use disorder in British Columbia, Canada.
    Socias ME; Scheuermeyer FX; Cui Z; Mok WY; Crabtree A; Fairbairn N; Nolan S; Slaunwhite A; Ti L
    Addiction; 2023 Nov; 118(11):2128-2138. PubMed ID: 37488683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcoholics Anonymous and other 12-step programs for alcohol use disorder.
    Kelly JF; Humphreys K; Ferri M
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012880. PubMed ID: 32159228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study.
    Addolorato G; Leggio L; Ferrulli A; Cardone S; Vonghia L; Mirijello A; Abenavoli L; D'Angelo C; Caputo F; Zambon A; Haber PS; Gasbarrini G
    Lancet; 2007 Dec; 370(9603):1915-22. PubMed ID: 18068515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
    Avanceña ALV; Miller N; Uttal SE; Hutton DW; Mellinger JL
    J Hepatol; 2021 Jun; 74(6):1286-1294. PubMed ID: 33326815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alcohol use disorders and the risk of progression of liver disease in people with hepatitis C virus infection - a systematic review.
    Llamosas-Falcón L; Shield KD; Gelovany M; Manthey J; Rehm J
    Subst Abuse Treat Prev Policy; 2020 Jun; 15(1):45. PubMed ID: 32605584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alcohol as a risk factor for liver cirrhosis: a systematic review and meta-analysis.
    Rehm J; Taylor B; Mohapatra S; Irving H; Baliunas D; Patra J; Roerecke M
    Drug Alcohol Rev; 2010 Jul; 29(4):437-45. PubMed ID: 20636661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baclofen Combined With Psychosocial Care is Useful and Safe in Alcohol-Related Cirrhosis Patients: A Real-Life Multicenter Study.
    Barrault C; Alqallaf S; Lison H; Lamote-Chaouche I; Bourcier V; Laugier J; Thevenot T; Labarriere D; Ripault MP; Le Gruyer A; Costentin C; Behar V; Hagege H; Jung C; Cadranel JF;
    Alcohol Alcohol; 2023 Mar; 58(2):117-124. PubMed ID: 36527321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Attitudes about medications for alcohol use disorder among individuals with serious mental illness: A health belief model analysis.
    Bromley E; Tarn DM; McCreary M; Hurley B; Ober AJ; Watkins KE
    J Subst Abuse Treat; 2020 Jul; 114():108007. PubMed ID: 32527506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacotherapies for Adults With Alcohol Use Disorders: A Systematic Review and Network Meta-analysis.
    Bahji A; Bach P; Danilewitz M; Crockford D; Devoe DJ; El-Guebaly N; Saitz R
    J Addict Med; 2022 Nov-Dec 01; 16(6):630-638. PubMed ID: 35653782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.